Meta AnalysisID 495
马鞭草治疗成人和儿童急性呼吸道感染：系统评价
CRD42021279377
To determine whether Verbena officinalis is effective and safe to be used in uncomplicated acute respiratory tract infections (ARTIs).
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Herb: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 495
- Evidence Id
- 9053
- Core Evidence Id
- 9053
- Source Meta Analysis Id
- 469
- Herb2 Meta Analysis Id
- HBMA000469
- Crd Id
- CRD42021279377
- Title
- Verbena officinalis for acute respiratory tract infections in adults and children: a systematic review
- Review Question
- To determine whether Verbena officinalis is effective and safe to be used in uncomplicated acute respiratory tract infections (ARTIs).
- Study Type Included
- Published and unpublished randomised controlled trials (RCTs) and data collected prior to cross-over in crossover trials. Controlled before and after studies, interrupted time series (ITS) studies, quasi-RCTs and non-experimental studies will not be included due to their potential high risk of bias.
- Condition Being Studied
- Acute respiratory tract infections
- Participant
- Patients (all age groups) with either an acute respiratory tract infection (ARI) diagnosis or have presented with symptoms of ARI. These will include hospital admissions. A clinical diagnosis of ARI will be the main inclusion criterion. Diagnoses of upper or lower ARIs include the common cold, influenza, Covid 19, rhinosinusitis, otitis media, laryngitis, tonsillitis, pharyngitis, tracheitis, bronchitis, acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Symptoms of ARIs will include sore throat, fever, runny nose, cough, dyspnoea and discoloured sputum with a duration of less than three weeks. Trials will be excluded if they recruited participants with a serious condition or comorbidity which necessitates treatment with antibiotics as an established therapy, such as pneumonia or tuberculosis (unless patients are recruited/reported separately). Exclusion also applies to trials that included patients who required hospital admission for severe pneumonia or had a known immune deficiency
- Animal
- Human Disease Modelled
- Intervention
- Any preparation of the aerial parts from Verbena officinalis, either as a single herb or within a formula which includes oral, nasal, or external use, apart from injection. There are no restrictions concerning dosage, methods of dosing or treatment duration.
- Comparator Control
- No intervention, placebo; orthodox medical interventions such as antivirals, antibiotics, anti-inflammatories, steroids or corticosteroids will be included.
- Main Outcome
- 1). Participant self-reported or clinician/observer assessment on overall ARI symptomatic relief, either single or overall symptoms. 2). Percent of patients with reported resolution by study follow-up, plus mean time to reported remission or resolution of overall ARI symptoms, data permitting. This may be measured directly, through patient or clinician/observer report, or indirectly as the time to return to normal activities. 3). Adverse events (AEs): These include any anaphylactic, allergic reactions, hypersensitivity reactions, or complications of taking Glycyrrhiza. Information regarding AEs due to interactions among Glycyrrhiza in combination with other remedies or potential interactions with medications prescribed for co-morbidities will also be collected. Measures of effect · Changes on visual analogue scales (VAS) · Changes in symptoms scored on a Likert-type scale · Global assessment of symptom improvement by the patient · Global assessment of symptom improvement observed by the clinician Where possible, the analyses will be based on Intention to treat (ITT) data on each outcome provided for every randomised participant from the individual trials. Where possible, for continuous outcomes, the end of treatment scores rather than change from baseline scores will be extracted. For continuous data, due to the anticipated variability in the populations and interventions of included trials, a generic inverse variance random effects model will be used to pool the mean differences (MD) with 95% confidence intervals (CI) to incorporate heterogeneity (Higgins and Green, 2011, Murad et al., 2015). If the units of the outcome measures used across studies were not consistent, the effects as standardised mean differences (SMD) will be reported. An overall effect size of 0.2-0.5 is regarded as small, 0.5-0.8 as moderate and more than 0.8 as large (Cohen, 1988). For dichotomous data, a random effects method will be used to pool the summary risk ratio (RR) with 95% CI.
- Outcome Measure
- Additional Outcome
- Percent of patients with reported resolution by study follow-up, plus mean time to reported remission or resolution of overall ARI symptoms, data permitting. Measures of effect This may be measured directly, through patient or clinician/observer report, or indirectly as the time to return to normal activities. All other criteria will be the same as for the primary outcome (e.g. odd ratios, etc)
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Adult; Child; Humans; Respiratory Tract Infections; Verbena
- Contact
- Jeanne Trill [email protected]
- Organisational Affiliation
- University of Southampton
- Funding Source
- Innovate UK, and the National Key Research and Development Project
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- England
- Review Stage
- Review Ongoing
- First Submission Date
- 2021-09-20
- Registration Date
- 2021-09-21
- Anticipated Start Date
- 2021-09-21
- Anticipated Completion Date
- 2022-04-01
- Title Cn
- 马鞭草治疗成人和儿童急性呼吸道感染：系统评价
- Title En
- Verbena officinalis for acute respiratory tract infections in adults and children: a systematic review
- Bilingual Status
- complete